NCT06805305 2026-04-14
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2 Recruiting
Clinical Trials
61 trialsNCT07326566 2026-04-14
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT02800486 2026-04-13
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
Phase 2 Recruiting
NCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
NCT07511725 2026-04-06
PRISM
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06319027 2026-04-03
GABLE
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT04559230 2026-03-30
Sacituzumab Govitecan in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT07225621 2026-03-19
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical, Inc.
Phase 2 Recruiting
NCT07476794 2026-03-17
TEMPO
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT05463848 2026-03-04
Surgical Pembro +/- Olaparib w TMZ for rGBM
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05607407 2026-03-04
Methimazole in Patients With Progressive Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT06058988 2026-02-23
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04765514 2026-02-13
Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT07263438 2026-02-13
Phenix
Centre Hospitalier Universitaire Vaudois
Phase 2 Recruiting
NCT06061809 2026-02-12
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio, Inc.
Phase 2 Recruiting
NCT05653622 2026-02-04
SIB-DOPA
Centre Paul Strauss
Phase 2 Recruiting
NCT05653635 2026-02-04
ReciDOPA
Centre Paul Strauss
Phase 2 Recruiting
NCT02394626 2026-02-02
RESURGE
Insel Gruppe AG, University Hospital Bern
Phase 2 Recruiting
NCT05629702 2026-01-30
ARISTOCRAT
University of Birmingham
Phase 2 Recruiting
NCT05683808 2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2 Recruiting
NCT07364786 2026-01-23
AFGBMBiop
Skane University Hospital
Phase 2 Recruiting
NCT04623931 2026-01-14
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05465954 2026-01-12
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Mayo Clinic
Phase 2 Recruiting
NCT05871021 2026-01-09
PRIDE
University Hospital Tuebingen
Phase 2 Recruiting
NCT06558214 2026-01-07
OPTIMUS PRIME
University of Florida
Phase 2 Recruiting
NCT05879250 2025-12-30
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 2 Recruiting
NCT06991101 2025-12-26
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Baptist Health South Florida
Phase 2 Recruiting
NCT05708352 2025-12-24
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT07285044 2025-12-22
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT04945148 2025-11-21
OPTIMUM
Hopital Foch
Phase 2 Recruiting
NCT05052957 2025-11-21
hSTAR GBM
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT02977780 2025-11-10
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06069726 2025-10-31
MOAB
Duke University
Phase 2 Recruiting
NCT05864534 2025-10-03
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Northwestern University
Phase 2 Recruiting
NCT07193654 2025-09-26
Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06649851 2025-09-25
G-CSF After Chemo-radiation in Patients With Glioblastoma
Massachusetts General Hospital
Phase 2 Recruiting
NCT06835803 2025-09-18
ELITE-GBM
Brigham and Women's Hospital
Phase 2 Recruiting
NCT04863950 2025-08-27
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT06177964 2025-08-17
Lerapolturev (PVSRIPO) in GBM
Duke University
Phase 2 Recruiting
NCT07003542 2025-08-11
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT06356883 2025-08-07
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
Université de Sherbrooke
Phase 2 Recruiting
NCT05929495 2025-07-25
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
University of Milano Bicocca
Phase 2 Recruiting
NCT04523688 2025-07-22
Combi G-Vax
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT04765098 2025-06-26
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT06598787 2025-05-07
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06936046 2025-04-20
Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06016452 2025-04-11
CHROME
Tata Memorial Centre
Phase 2 Recruiting